AstraZeneca Sharpens Andexanet Strategy With Completed Phase I Dosing Study
AstraZeneca ($~AZN) announced an update on their ongoing clinical study.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
AstraZeneca is running a Phase I trial called “A Phase I, Randomized, Single-blind, Placebo-controlled Study to Further Characterize Andexanet Posology and Assess the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants.” The goal is to fine tune dosing of andexanet and see how it interacts with follow up blood-thinning treatment, a key step for safer use in real world care.
The main treatment tested is andexanet alfa, given by IV bolus and infusion, aimed at reversing the effect of certain oral blood thinners. The study also uses rivaroxaban, apixaban and enoxaparin as background drugs, along with placebo, to map how andexanet behaves across common anticoagulant regimens.
This is an interventional, randomized study in healthy volunteers, with parallel groups receiving different drug combinations. It is single blind, so participants do not know which regimen they get, and the primary goal is treatment focused, meaning the design aims to support future clinical use rather than only describe biology.
The trial is listed as completed, with initial submission on 2025-11-27, pointing to a standard early stage timeline from set up to execution. The latest update was filed on 2026-07-08, which signals recent data handling and suggests results may be moving toward analysis and later publication or regulatory dialogue.
For investors, a clean Phase I completion on andexanet dosing helps de risk AstraZeneca’s plans in the anticoagulation reversal space, which sits alongside established agents and specialty competitors. If later data show clear safety and predictable use with drugs like apixaban and rivaroxaban, this could support a premium profile, though broader market impact will depend on Phase II/III results and payer uptake.
The study is completed and recently updated, and further details are available on the ClinicalTrials portal for investors tracking AstraZeneca’s anticoagulation pipeline.
To learn more about ~AZN’s potential, visit the AstraZeneca drug pipeline page.
